Share Price and Basic Stock Data
Last Updated: December 9, 2025, 8:13 pm
| PEG Ratio | 0.49 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Brooks Laboratories Ltd operates in the pharmaceuticals sector, a field characterized by intense competition and regulatory scrutiny. As of the latest reporting, the company’s stock price stood at ₹95.2, with a market capitalization of ₹281 Cr. Over the past few quarters, revenue trends have showcased volatility. For instance, sales peaked at ₹24.32 Cr in September 2023, a noticeable recovery from the lower ₹12.61 Cr recorded in March 2023. However, the trailing twelve months (TTM) sales of ₹90.14 Cr indicate that the company is still grappling with revenue consistency. The revenue trajectory reflects a broader industry challenge, as many pharmaceutical firms are under pressure to innovate while managing costs effectively. Given these dynamics, Brooks Laboratories appears to be navigating a complex landscape, with its performance largely hinging on operational efficiency and market conditions.
Profitability and Efficiency Metrics
Profitability remains a critical concern for Brooks Laboratories, as evidenced by its operating profit margin (OPM) which has fluctuated significantly. The OPM for the trailing twelve months is reported at -3.37%, underscoring the challenges the company faces in managing its cost structure. Particularly alarming is the spike in operating losses, which reached ₹29.73 Cr in March 2023. Although there was some improvement with a reported operating loss of ₹8.04 Cr for March 2025, this still indicates that the company has not yet achieved sustainable profitability. Efficiency metrics, such as the cash conversion cycle (CCC), stood at 58.54 days, suggesting a moderate ability to convert investments into cash flows. While the interest coverage ratio of 5.66x appears to provide some cushion against financial distress, the overall profitability picture remains a concern for potential investors.
Balance Sheet Strength and Financial Ratios
Examining the balance sheet, Brooks Laboratories reveals a mixed picture of financial health. The company reported total reserves of ₹86 Cr against borrowings of just ₹8 Cr, indicating a low debt burden and a strong equity position. The price-to-book value ratio stands at 3.23x, reflecting market expectations of future growth, but also suggesting that investors may be pricing in recovery hopes rather than current performance. Furthermore, the return on equity (ROE) is recorded at 12.2%, which, while not extraordinary, indicates that the company is generating some returns for its shareholders. However, the return on capital employed (ROCE) is a more sobering 9.93%, highlighting inefficiencies in utilizing capital for profit generation. These financial ratios suggest that while Brooks Laboratories has a solid foundation, it must enhance operational efficiencies to leverage its equity effectively.
Shareholding Pattern and Investor Confidence
Investor confidence in Brooks Laboratories appears to be waning, as reflected in its shareholding pattern. Promoter holdings have decreased from 66.41% in March 2023 to 52.62% in March 2025, indicating a potential concern about insider confidence in the company’s future. On the other hand, domestic institutional investors (DIIs) have shown increased interest, raising their stake to 10.38% by March 2025. This shift could signal a cautious optimism among institutional players, who may be banking on a turnaround strategy. However, the lack of foreign institutional investment (FIIs) remains a red flag, as it reflects a broader hesitance from global investors. With over 10,000 shareholders, the public’s stake is also significant at 37%, suggesting a diverse ownership base that could influence the company’s strategic direction in the future.
Outlook, Risks, and Final Insight
Looking ahead, Brooks Laboratories faces a mixed bag of opportunities and risks. The potential for revenue growth exists, particularly if the company can leverage its reserves and improve its operational efficiencies. However, profitability remains a significant hurdle, and the company must address its cost structure to avoid prolonged losses. Additionally, the declining promoter shareholding could shake investor confidence further if not addressed. Regulatory challenges in the pharmaceutical sector also pose risks that can impact operations. Investors might consider these factors when evaluating Brooks Laboratories; while there is room for growth, the path to recovery appears fraught with challenges. The company must act decisively to enhance its profitability and restore investor trust to realize its potential in a competitive market.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Brooks Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 144 Cr. | 115 | 247/84.3 | 32.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,214 Cr. | 384 | 479/192 | 87.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.4 Cr. | 45.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.7 Cr. | 29.8 | 30.5/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,299.59 Cr | 1,156.92 | 52.10 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17.12 | 18.08 | 15.30 | 12.61 | 15.70 | 24.32 | 21.75 | 17.72 | 17.93 | 20.79 | 20.52 | 23.32 | 25.51 |
| Expenses | 25.72 | 27.30 | 23.85 | 16.31 | 19.61 | 25.42 | 25.12 | 27.25 | 19.85 | 24.20 | 22.02 | 24.58 | 22.38 |
| Operating Profit | -8.60 | -9.22 | -8.55 | -3.70 | -3.91 | -1.10 | -3.37 | -9.53 | -1.92 | -3.41 | -1.50 | -1.26 | 3.13 |
| OPM % | -50.23% | -51.00% | -55.88% | -29.34% | -24.90% | -4.52% | -15.49% | -53.78% | -10.71% | -16.40% | -7.31% | -5.40% | 12.27% |
| Other Income | 0.03 | 0.40 | 0.45 | 0.03 | 0.05 | 0.09 | 0.16 | 0.65 | 0.07 | 0.20 | 0.03 | 0.62 | 7.15 |
| Interest | 0.62 | 0.63 | 0.75 | 0.18 | 0.17 | 0.19 | 0.21 | 0.27 | 0.16 | 0.32 | 0.28 | 0.26 | 0.30 |
| Depreciation | 1.98 | 2.28 | 2.33 | 0.44 | 0.44 | 0.44 | 0.43 | 0.46 | 0.40 | 0.43 | 0.38 | 0.39 | 0.39 |
| Profit before tax | -11.17 | -11.73 | -11.18 | -4.29 | -4.47 | -1.64 | -3.85 | -9.61 | -2.41 | -3.96 | -2.13 | -1.29 | 9.59 |
| Tax % | -15.85% | -32.82% | -15.21% | 0.00% | 0.00% | 0.00% | 0.78% | 0.00% | 0.00% | 0.00% | 0.00% | 13.95% | 0.00% |
| Net Profit | -9.40 | -7.87 | -9.48 | -4.29 | -4.47 | -1.64 | -3.88 | -9.61 | -2.41 | -3.96 | -2.13 | -1.46 | 9.58 |
| EPS in Rs | -2.63 | -1.79 | -1.92 | -1.64 | -1.71 | -0.62 | -1.48 | -3.66 | -0.92 | -1.51 | -0.81 | -0.50 | 3.25 |
Last Updated: August 20, 2025, 12:35 pm
Below is a detailed analysis of the quarterly data for Brooks Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 25.51 Cr.. The value appears strong and on an upward trend. It has increased from 23.32 Cr. (Mar 2025) to 25.51 Cr., marking an increase of 2.19 Cr..
- For Expenses, as of Jun 2025, the value is 22.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 24.58 Cr. (Mar 2025) to 22.38 Cr., marking a decrease of 2.20 Cr..
- For Operating Profit, as of Jun 2025, the value is 3.13 Cr.. The value appears strong and on an upward trend. It has increased from -1.26 Cr. (Mar 2025) to 3.13 Cr., marking an increase of 4.39 Cr..
- For OPM %, as of Jun 2025, the value is 12.27%. The value appears strong and on an upward trend. It has increased from -5.40% (Mar 2025) to 12.27%, marking an increase of 17.67%.
- For Other Income, as of Jun 2025, the value is 7.15 Cr.. The value appears strong and on an upward trend. It has increased from 0.62 Cr. (Mar 2025) to 7.15 Cr., marking an increase of 6.53 Cr..
- For Interest, as of Jun 2025, the value is 0.30 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.26 Cr. (Mar 2025) to 0.30 Cr., marking an increase of 0.04 Cr..
- For Depreciation, as of Jun 2025, the value is 0.39 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.39 Cr..
- For Profit before tax, as of Jun 2025, the value is 9.59 Cr.. The value appears strong and on an upward trend. It has increased from -1.29 Cr. (Mar 2025) to 9.59 Cr., marking an increase of 10.88 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 13.95% (Mar 2025) to 0.00%, marking a decrease of 13.95%.
- For Net Profit, as of Jun 2025, the value is 9.58 Cr.. The value appears strong and on an upward trend. It has increased from -1.46 Cr. (Mar 2025) to 9.58 Cr., marking an increase of 11.04 Cr..
- For EPS in Rs, as of Jun 2025, the value is 3.25. The value appears strong and on an upward trend. It has increased from -0.50 (Mar 2025) to 3.25, marking an increase of 3.75.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:33 am
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 77.25 | 91.18 | 63.20 | 79.49 | 82.56 | 90.14 |
| Expenses | 76.68 | 105.43 | 92.93 | 97.36 | 90.60 | 93.18 |
| Operating Profit | 0.57 | -14.25 | -29.73 | -17.87 | -8.04 | -3.04 |
| OPM % | 0.74% | -15.63% | -47.04% | -22.48% | -9.74% | -3.37% |
| Other Income | 0.68 | 0.80 | 0.57 | 0.92 | 0.88 | 8.00 |
| Interest | 3.10 | 3.10 | 2.18 | 0.84 | 1.03 | 1.16 |
| Depreciation | 7.14 | 7.35 | 7.03 | 1.77 | 1.60 | 1.59 |
| Profit before tax | -8.99 | -23.90 | -38.37 | -19.56 | -9.79 | 2.21 |
| Tax % | 115.46% | -19.21% | -19.08% | 0.15% | 1.84% | |
| Net Profit | -19.38 | -19.31 | -31.04 | -19.59 | -9.97 | 2.03 |
| EPS in Rs | -7.40 | -4.31 | -7.97 | -7.46 | -3.38 | 0.43 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.36% | -60.75% | 36.89% | 49.11% |
| Change in YoY Net Profit Growth (%) | 0.00% | -61.11% | 97.63% | 12.22% |
Brooks Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2021-2022 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -3% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 4% |
| TTM: | 112% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | 3% |
| 1 Year: | 18% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -22% |
| Last Year: | -12% |
Last Updated: September 5, 2025, 1:25 am
Balance Sheet
Last Updated: December 4, 2025, 1:04 am
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 26 | 29 | 29 |
| Reserves | 54 | 63 | 49 | 39 | 69 | 86 |
| Borrowings | 31 | 25 | 7 | 6 | 8 | 8 |
| Other Liabilities | 52 | 83 | 29 | 19 | 18 | 16 |
| Total Liabilities | 162 | 196 | 110 | 90 | 124 | 140 |
| Fixed Assets | 108 | 110 | 15 | 14 | 14 | 13 |
| CWIP | 1 | 15 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 64 | 43 | 74 | 86 |
| Other Assets | 54 | 71 | 31 | 34 | 36 | 40 |
| Total Assets | 162 | 196 | 110 | 90 | 124 | 140 |
Below is a detailed analysis of the balance sheet data for Brooks Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 29.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 29.00 Cr..
- For Reserves, as of Sep 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 69.00 Cr. (Mar 2025) to 86.00 Cr., marking an increase of 17.00 Cr..
- For Borrowings, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 16.00 Cr.. The value appears to be improving (decreasing). It has decreased from 18.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 140.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 124.00 Cr. (Mar 2025) to 140.00 Cr., marking an increase of 16.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 74.00 Cr. (Mar 2025) to 86.00 Cr., marking an increase of 12.00 Cr..
- For Other Assets, as of Sep 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2025) to 40.00 Cr., marking an increase of 4.00 Cr..
- For Total Assets, as of Sep 2025, the value is 140.00 Cr.. The value appears strong and on an upward trend. It has increased from 124.00 Cr. (Mar 2025) to 140.00 Cr., marking an increase of 16.00 Cr..
Notably, the Reserves (86.00 Cr.) exceed the Borrowings (8.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Free Cash Flow | -30.43 | -39.25 | -36.73 | -23.87 | -16.04 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 64.73 | 70.69 | 73.64 | 74.94 | 88.38 |
| Inventory Days | 177.86 | 156.51 | 79.89 | 60.49 | 62.10 |
| Days Payable | 233.26 | 159.24 | 165.21 | 97.25 | 91.94 |
| Cash Conversion Cycle | 9.34 | 67.96 | -11.69 | 38.18 | 58.54 |
| Working Capital Days | -84.81 | 33.99 | -37.48 | 33.57 | 43.28 |
| ROCE % | -15.50% | -30.45% | -24.70% | -9.90% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Business Cycle Fund | 528,937 | 0.84 | 6.69 | 528,937 | 2025-04-22 17:25:39 | 0% |
| Quant Healthcare Fund | 276,708 | 1.99 | 3.5 | 276,708 | 2025-04-22 17:25:39 | 0% |
| Quant Small Cap Fund | 187,346 | 0.02 | 2.37 | 187,346 | 2025-04-22 17:25:39 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -3.72 | -7.65 | -12.57 | -7.82 | -7.84 |
| Diluted EPS (Rs.) | -3.72 | -7.65 | -12.57 | -7.82 | -7.84 |
| Cash EPS (Rs.) | 1.57 | 1.26 | -8.39 | -4.84 | -4.95 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 33.30 | 24.99 | 29.94 | 54.37 | 32.04 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 33.30 | 24.99 | 29.94 | 54.37 | 32.04 |
| Revenue From Operations / Share (Rs.) | 28.03 | 30.28 | 25.59 | 36.87 | 31.27 |
| PBDIT / Share (Rs.) | 1.98 | 1.59 | -10.61 | -5.44 | 0.50 |
| PBIT / Share (Rs.) | 1.43 | 0.91 | -13.46 | -8.42 | -2.38 |
| PBT / Share (Rs.) | 1.08 | 0.59 | -14.20 | -9.67 | -3.64 |
| Net Profit / Share (Rs.) | 1.02 | 0.58 | -11.23 | -7.82 | -7.84 |
| NP After MI And SOA / Share (Rs.) | -3.38 | -7.46 | -8.46 | -6.55 | -7.84 |
| PBDIT Margin (%) | 7.05 | 5.24 | -41.47 | -14.76 | 1.62 |
| PBIT Margin (%) | 5.11 | 3.01 | -52.59 | -22.83 | -7.62 |
| PBT Margin (%) | 3.86 | 1.95 | -55.48 | -26.23 | -11.63 |
| Net Profit Margin (%) | 3.65 | 1.92 | -43.89 | -21.20 | -25.07 |
| NP After MI And SOA Margin (%) | -12.07 | -24.64 | -33.06 | -17.77 | -25.08 |
| Return on Networth / Equity (%) | -10.15 | -29.87 | -28.26 | -25.67 | -24.47 |
| Return on Capital Employeed (%) | 4.18 | 3.56 | -43.41 | -14.14 | -5.98 |
| Return On Assets (%) | -8.05 | -21.66 | -19.06 | -8.26 | -11.95 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.14 | 0.18 |
| Total Debt / Equity (X) | 0.06 | 0.07 | 0.07 | 0.38 | 0.35 |
| Asset Turnover Ratio (%) | 0.77 | 0.79 | 0.41 | 0.57 | 0.00 |
| Current Ratio (X) | 1.48 | 1.35 | 0.83 | 1.25 | 0.78 |
| Quick Ratio (X) | 1.08 | 0.93 | 0.49 | 0.68 | 0.41 |
| Inventory Turnover Ratio (X) | 5.00 | 4.28 | 2.14 | 2.31 | 0.00 |
| Interest Coverage Ratio (X) | 5.66 | 4.94 | -12.01 | -4.34 | 0.40 |
| Interest Coverage Ratio (Post Tax) (X) | 3.93 | 2.81 | -11.87 | -5.24 | -5.25 |
| Enterprise Value (Cr.) | 322.19 | 247.92 | 159.23 | 271.01 | 179.90 |
| EV / Net Operating Revenue (X) | 3.90 | 3.12 | 2.52 | 2.98 | 2.33 |
| EV / EBITDA (X) | 55.34 | 59.41 | -6.07 | -20.15 | 143.19 |
| MarketCap / Net Operating Revenue (X) | 3.84 | 3.06 | 2.45 | 1.97 | 1.99 |
| Price / BV (X) | 3.23 | 3.71 | 2.09 | 2.84 | 1.94 |
| Price / Net Operating Revenue (X) | 3.84 | 3.06 | 2.45 | 1.97 | 1.99 |
| EarningsYield | -0.03 | -0.08 | -0.13 | -0.09 | -0.12 |
After reviewing the key financial ratios for Brooks Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -3.72. This value is below the healthy minimum of 5. It has increased from -7.65 (Mar 24) to -3.72, marking an increase of 3.93.
- For Diluted EPS (Rs.), as of Mar 25, the value is -3.72. This value is below the healthy minimum of 5. It has increased from -7.65 (Mar 24) to -3.72, marking an increase of 3.93.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 3. It has increased from 1.26 (Mar 24) to 1.57, marking an increase of 0.31.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.30. It has increased from 24.99 (Mar 24) to 33.30, marking an increase of 8.31.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.30. It has increased from 24.99 (Mar 24) to 33.30, marking an increase of 8.31.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 28.03. It has decreased from 30.28 (Mar 24) to 28.03, marking a decrease of 2.25.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.98. This value is below the healthy minimum of 2. It has increased from 1.59 (Mar 24) to 1.98, marking an increase of 0.39.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is within the healthy range. It has increased from 0.91 (Mar 24) to 1.43, marking an increase of 0.52.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.08. This value is within the healthy range. It has increased from 0.59 (Mar 24) to 1.08, marking an increase of 0.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.02. This value is below the healthy minimum of 2. It has increased from 0.58 (Mar 24) to 1.02, marking an increase of 0.44.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -3.38. This value is below the healthy minimum of 2. It has increased from -7.46 (Mar 24) to -3.38, marking an increase of 4.08.
- For PBDIT Margin (%), as of Mar 25, the value is 7.05. This value is below the healthy minimum of 10. It has increased from 5.24 (Mar 24) to 7.05, marking an increase of 1.81.
- For PBIT Margin (%), as of Mar 25, the value is 5.11. This value is below the healthy minimum of 10. It has increased from 3.01 (Mar 24) to 5.11, marking an increase of 2.10.
- For PBT Margin (%), as of Mar 25, the value is 3.86. This value is below the healthy minimum of 10. It has increased from 1.95 (Mar 24) to 3.86, marking an increase of 1.91.
- For Net Profit Margin (%), as of Mar 25, the value is 3.65. This value is below the healthy minimum of 5. It has increased from 1.92 (Mar 24) to 3.65, marking an increase of 1.73.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -12.07. This value is below the healthy minimum of 8. It has increased from -24.64 (Mar 24) to -12.07, marking an increase of 12.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is -10.15. This value is below the healthy minimum of 15. It has increased from -29.87 (Mar 24) to -10.15, marking an increase of 19.72.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.18. This value is below the healthy minimum of 10. It has increased from 3.56 (Mar 24) to 4.18, marking an increase of 0.62.
- For Return On Assets (%), as of Mar 25, the value is -8.05. This value is below the healthy minimum of 5. It has increased from -21.66 (Mar 24) to -8.05, marking an increase of 13.61.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has decreased from 0.07 (Mar 24) to 0.06, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.77. It has decreased from 0.79 (Mar 24) to 0.77, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 1.5. It has increased from 1.35 (Mar 24) to 1.48, marking an increase of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 1.08. This value is within the healthy range. It has increased from 0.93 (Mar 24) to 1.08, marking an increase of 0.15.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.00. This value is within the healthy range. It has increased from 4.28 (Mar 24) to 5.00, marking an increase of 0.72.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.66. This value is within the healthy range. It has increased from 4.94 (Mar 24) to 5.66, marking an increase of 0.72.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.93. This value is within the healthy range. It has increased from 2.81 (Mar 24) to 3.93, marking an increase of 1.12.
- For Enterprise Value (Cr.), as of Mar 25, the value is 322.19. It has increased from 247.92 (Mar 24) to 322.19, marking an increase of 74.27.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.90. This value exceeds the healthy maximum of 3. It has increased from 3.12 (Mar 24) to 3.90, marking an increase of 0.78.
- For EV / EBITDA (X), as of Mar 25, the value is 55.34. This value exceeds the healthy maximum of 15. It has decreased from 59.41 (Mar 24) to 55.34, marking a decrease of 4.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.06 (Mar 24) to 3.84, marking an increase of 0.78.
- For Price / BV (X), as of Mar 25, the value is 3.23. This value exceeds the healthy maximum of 3. It has decreased from 3.71 (Mar 24) to 3.23, marking a decrease of 0.48.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.06 (Mar 24) to 3.84, marking an increase of 0.78.
- For EarningsYield, as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has increased from -0.08 (Mar 24) to -0.03, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Brooks Laboratories Ltd:
- Net Profit Margin: 3.65%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.18% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -10.15% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.08
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.4 (Industry average Stock P/E: 52.1)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.65%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village Kishanpura,. Solan District Himachal Pradesh 174101 | investors@brookslabs.net http://www.brookslabs.net |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bhushan Singh Rana | Whole Time Director |
| Mr. Jitendra Pratap Singh | Whole Time Director |
| Mr. Durga Shankar Maity | Whole Time Director |
| Mr. Manav Mahajan | Independent Director |
| Mr. Lalit Mahajan | Independent Director |
| Dr. Usha Singh | Independent Director |
FAQ
What is the intrinsic value of Brooks Laboratories Ltd?
Brooks Laboratories Ltd's intrinsic value (as of 09 December 2025) is 79.81 which is 17.47% lower the current market price of 96.70, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 285 Cr. market cap, FY2025-2026 high/low of 203/93.5, reserves of ₹86 Cr, and liabilities of 140 Cr.
What is the Market Cap of Brooks Laboratories Ltd?
The Market Cap of Brooks Laboratories Ltd is 285 Cr..
What is the current Stock Price of Brooks Laboratories Ltd as on 09 December 2025?
The current stock price of Brooks Laboratories Ltd as on 09 December 2025 is 96.7.
What is the High / Low of Brooks Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Brooks Laboratories Ltd stocks is 203/93.5.
What is the Stock P/E of Brooks Laboratories Ltd?
The Stock P/E of Brooks Laboratories Ltd is 20.4.
What is the Book Value of Brooks Laboratories Ltd?
The Book Value of Brooks Laboratories Ltd is 39.3.
What is the Dividend Yield of Brooks Laboratories Ltd?
The Dividend Yield of Brooks Laboratories Ltd is 0.00 %.
What is the ROCE of Brooks Laboratories Ltd?
The ROCE of Brooks Laboratories Ltd is 9.93 %.
What is the ROE of Brooks Laboratories Ltd?
The ROE of Brooks Laboratories Ltd is 12.2 %.
What is the Face Value of Brooks Laboratories Ltd?
The Face Value of Brooks Laboratories Ltd is 10.0.